Age, albumin level, β2‐microglobulin, level incidence of thrombocytopenia (defined as platelet count <150/mL), lines of therapy, prior pomalidomide/carfilzomib exposure, sex, refractory status. This evidence concerns the gene HLA-G and Thrombocytopenia.